Bronchial AsthmaNCT07620691
N95 Masks for Lung Health While Golfing During Wildfire Season
A study testing N95 mask in people with Bronchial Asthma, run by University of Saskatchewan at 1 site in Canada.
Trial summary
Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Bronchial Asthma
- What is being tested?
- N95 mask
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 26 May 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Golf on a regular basis (two or more times per week)
Who cannot join
- Smoker
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Saskatchewan
Saskatoon, SK - Saskatchewan, S7N 5B2
Philip Chilibeck, PhD, 3062303849, phil.chilibeck@usask.ca
About this study
Official title: A Pilot / Feasibility Study on Cardiorespiratory Health of Golfers During Wildfire Season
Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.
Read the detailed description
Wildfire smoke negatively affects lung health. Across North American, millions of people are exposed to wildfire smoke most summers. The purpose of our study is to determine whether people who golf regularly (two or more times per week) can use N95 masks to protect their lungs from wildfire smoke. Forty regular golfers will be randomized to receive N95 masks or not to receive masks. All participants will be told to follow guidelines for outdoor activity based on Air Quality Health Index readings. Those randomized to wear N95 facemasks will be asked to wear these on days they golf where Air Quality Health Index indicates moderate risk or higher. The main outcome is compliance with wearing the N95 mask. Secondary outcomes include changes in lung function, blood pressure, and respiratory symptoms over two months.
- Conditions
- Bronchial Asthma
- Being tested
- N95 mask
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
N95 maskDevice
N95 mask to be worn outside when golfing when Air Quality Health Index reading indicates moderate risk or higher
| Study group | Role | What they receive |
|---|---|---|
| N95 mask | Experimental | N95 masks will be worn outdoors when Air Quality Health Index indicates moderate risk or higher (4 or higher) Receives: Device: N95 mask |
| No N95 mask | No intervention | No N95 masks will be provided to participants |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in compliance with wearing of N95 masks (number of times divided by days with moderate or higher air pollution)
compliance with wearing the N95 masks
Measured: 8 weeks
Secondary outcomes (6)
Change in forced expiratory volume in one second (L)
Force expiratory volume in one second measured with spirometry
Measured: 8 weeks
Change in forced vital capacity (mL)
Forced vital capacity measured by spirometry
Measured: 8 weeks
Change in forced expiratory flow at 25% to 75% of vital capacity (mL)
forced expiratory flow at 25% to 75% of vital capacity measured by spirometry
Measured: 8 weeks
Change in respiratory symptoms (score out of 12)
Respiratory symptoms determined by the Dyspnoea-12 questionnaire
Measured: 8 weeks
Change in systolic blood pressure (mmHg)
Systolic blood pressure measured by an automatic sphygmomanometer
Measured: 8 weeks
Change in diastolic blood pressure (mmHg)
Diastolic blood pressure measured by an automatic sphygmomanometer
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start26 May 2026
- Primary completion1 Sep 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bronchial AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Saskatchewan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Phil Chilibeck, University of Saskatchewan
- Investigators
- Philip Chilibeck, PhD, Principal investigator, University of Saskatchewan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07620691
- Sponsor's protocol ID
- 6402
- Status last verified
- May 2026
- First submitted
- 26 May 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot / Feasibility Study on Cardiorespiratory Health of Golfers During Wildfire Season
- ClinicalTrials.gov ID
- NCT07620691
- Acronym / sponsor ID
- 6402
- Conditions
- Bronchial Asthma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of SaskatchewanUniversity, hospital or other
- Study start
- 26 May 2026 (actual)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung health is negatively affected during wildfire season by increased smoke pollution. Wearing N95 masks protects lung health in the short-term. The purpose of our study is to assess whether wearing of N95 facemasks on days with moderate to high air pollution in people who go outside to golf on a regular basis (two or more times per week) for two months during the wildfire season projects lung health.
Detailed description
Wildfire smoke negatively affects lung health. Across North American, millions of people are exposed to wildfire smoke most summers. The purpose of our study is to determine whether people who golf regularly (two or more times per week) can use N95 masks to protect their lungs from wildfire smoke. Forty regular golfers will be randomized to receive N95 masks or not to receive masks. All participants will be told to follow guidelines for outdoor activity based on Air Quality Health Index readings. Those randomized to wear N95 facemasks will be asked to wear these on days they golf where Air Quality Health Index indicates moderate risk or higher. The main outcome is compliance with wearing the N95 mask. Secondary outcomes include changes in lung function, blood pressure, and respiratory symptoms over two months.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| N95 mask | Experimental | Device: N95 maskN95 masks will be worn outdoors when Air Quality Health Index indicates moderate risk or higher (4 or higher) |
| No N95 mask | No intervention | –No N95 masks will be provided to participants |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Golf on a regular basis (two or more times per week)
Key exclusion criteria (1 listed)
- Smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| N95 maskN95 mask to be worn outside when golfing when Air Quality Health Index reading indicates moderate risk or higher | Device | N95 mask |
Primary outcome
Change in compliance with wearing of N95 masks (number of times divided by days with moderate or higher air pollution)
Time frame: 8 weeks
compliance with wearing the N95 masks
6 secondary outcomes
Change in forced expiratory volume in one second (L)
Time frame: 8 weeks
Change in forced vital capacity (mL)
Time frame: 8 weeks
Change in forced expiratory flow at 25% to 75% of vital capacity (mL)
Time frame: 8 weeks
Change in respiratory symptoms (score out of 12)
Time frame: 8 weeks
Change in systolic blood pressure (mmHg)
Time frame: 8 weeks
Change in diastolic blood pressure (mmHg)
Time frame: 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
Related trials for Bronchial Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Philip Chilibeck, PhD principal investigator
University of Saskatchewan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing N95 mask in people with Bronchial Asthma, run by University of Saskatchewan at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philip Chilibeck, PhD (3062303849, phil.chilibeck@usask.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in compliance with wearing of N95 masks (number of times divided by days with moderate or higher air pollution) (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.